Publications
240
Citations
5,439
Est. group size
—
Recurring co-author estimate
Active years
48
Publishing since 1978
The publication record associated with this name spans a very wide range of unrelated fields, including quantum computing, environmental science, medical clinical trials, cardiology, and plant biology, suggesting the data likely combines multiple different authors sharing the same name. Because of this, no single coherent research program can be reliably described from the available records. Prospective students should treat these bibliographic details with caution and seek direct confirmation of a specific individual's actual work.
Publication counts fluctuate year to year, peaking around 2022-2023 and dropping in 2024-2025, with an average of about 6 per year over the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Mechanistic Insights into Adenovirus Resistance to UV: Dose-Dependent Repair and Delayed Suppression of Host DNA Damage Response
Environmental Science & Technology · 2025
- Hardware-efficient quantum error correction via concatenated bosonic qubits
Nature · 2025
- Chondrilla juncea L. (Asteraceae) a new plant for the alien flora of Chile
Gayana. Botánica · 2024
- Exploring Applicability of LLM-Powered Autonomous Agents to Solve Real-life Problems: Microsoft Entra ID Administration Agent (MEAN)
2024
- Presence of <i>Triatoma breyeri</i> (Reduviidae, Triatominae) in Bolivia
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- Hardware-efficient quantum error correction via concatenated bosonic qubits
arXiv (Cornell University) · 2024
- Presence of Triatoma breyeri (Reduviidae, Triatominae) in Bolivia
PLoS ONE · 2024
- Data from Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)
2023
- Data from Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)
2023
- Figure S1 from Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)
2023
- Figure S3 from Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)
2023
- Figure S4 from Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)
2023
- Figure S2 from Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)
2023
- Figure S3 from Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)
2023
- Figure S4 from Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)
2023
- Gayana. Botánica×6
- arXiv (Cornell University)×5
- Complementary Therapies in Medicine×2
- Cambridge University Press eBooks×2
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)×2
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile